* Immix Biopharma Inc is expected to show no change in quarterly revenue when it reports results on April 1 (estimated) for the period ending December 31 2023
*
* LSEG's mean analyst estimate for Immix Biopharma Inc is for a loss of 23 cents per share.
* The one available analyst rating on the shares is "buy".
* The mean earnings estimate of analysts was unchanged in the last three months.
* Wall Street's median 12-month price target for Immix Biopharma Inc is $14.00, above its last closing price of $3.07.
This summary was machine generated March 29 at 20:49 GMT. All figures in US dollars unless otherwise stated. (For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com)
Comments